

WAKE FOREST UNIVERSITY

SCHOOL OF MEDICINE
THE BOYMAN GRAY CAMPUS

OFFICE OF RESEARCH

<http://www.wfubmc.edu/or>

ADMINISTRATION

SALLY A. SHUMAKER, Ph.D.

ASSOCIATE DEAN FOR RESEARCH

DAVID P. FRIEDMAN, Ph.D.,

DEPUTY ASSOCIATE DEAN FOR RESEARCH

CHARLES E. McCALL, M.D.,

DEPUTY ASSOCIATE DEAN FOR RESEARCH

SUSAN M. HUTSON, Ph.D.

DEPUTY ASSOCIATE DEAN FOR RESEARCH

LAWRENCE D. SMITH

INTERIM DEPUTY ASSOCIATE DEAN FOR RESEARCH

VICKY ZICKMUND, DIRECTOR, RESEARCH

DEVELOPMENT, PLANNING AND OPERATIONS

DAVID LYONS, Ph.D., ASST. DIRECTOR,

RESEARCH DEVELOPMENT, PLANNING

AND OPERATIONS

KAREN KLEIN, RESEARCH SUPPORT CORE

PATTIE SMITH 60280

CAROL PIERPOINT 64548

INSTITUTIONAL REVIEW BOARD (IRB)

WESLEY BYERLY, PHARM.D., DIRECTOR

CHERYL CALOGERAKIS, ASST. DIRECTOR

JEANNIE TULLOCK 64781

AMANDA BOURNE 64542

SARAH MABIE 67252

MONITORING AND OVERSIGHT

WENDY MURRAY, MONITORING AND OVERSIGHT SPEC.

CHERYL ALBERT 67335

GRANTS ADMINISTRATION

LAWRENCE D. SMITH,

INTERIM DEPUTY ASSOCIATE DEAN FOR RESEARCH

PAULA MEANS, ASSISTANT DEAN FOR RESEARCH

KIM VARGAS, DIRECTOR

AMY COMER 64549

RYAN FAVREAU 35306

ANGELA HORTON 62382

INTRAMURAL RESEARCH SUPPORT COMMITTEE (IRSC)

AMY COMER 64549

ANGELA HORTON 62382

ANIMAL CARE AND USE COMMITTEE (ACUC)

BEVERLY GREENWOOD 63407

INDUSTRY RELATIONS

DAVID LYONS, Ph.D., INTERIM DIRECTOR

TERESA BUIE 62846

TINA PAGE 63157

ENVIRONMENTAL HEALTH AND SAFETY

DAVID A. BROWN, DIRECTOR

BIOSAFETY/INFECTION CONTROL 69375

RADIATION SAFETY 777-3180

CHEMICAL SAFETY 777-3099

ANIMAL RESOURCES PROGRAM

JEANNE WALLACE, D.V.M.,

DIRECTOR AND ATTENDING VETERINARIAN

BRUCE ROSE, M.S., M.B.A., OPERATIONS MANAGER

JAN SNYDER 64560

VICKIE HARDY, OPERATIONS MANAGER,

FRIEDBERG CAMPUS 61573

PURSUIT

RESEARCH INFORMATION BULLETIN Vol. 18, No. 8, October 2004

EXTRAMURAL SUPPORT FOR RESEARCH UP 17 PERCENT TO \$186 MILLION

Extramural support for research and related activities increased by more than \$28 million at Wake Forest University School of Medicine in the fiscal year ending June 30, 2004, resulting in the creation of at least 54 new jobs. The total was \$186 million, up from \$157.7 million in fiscal 2003 and double the outside support in fiscal 1998. "We appreciate the intellectual talent and hard work of our faculty in reaching this milestone," said Richard Dean, M.D., president and CEO of Wake Forest University Health Sciences, which operates the school. "It also demonstrates the economic impact of our research engine." The increase of \$28 million resulted in the creation of new jobs, including lab technicians, research assistants and associates, clerical support, faculty members and biostatisticians. Of the money, \$161.2 million went to individual research projects, and \$17.5 million went to the various research centers. Most of the money, 79 percent, came from federal agencies, mostly the National Institutes of Health and the Department of Defense. Industry-sponsored research increased sharply, from \$16.1 million to nearly \$21.5 million. Support from voluntary health agencies and foundations declined from \$15.5 million to \$14.1; state support increased from \$3.2 million to \$3.5 million. Grants to the Department of Public Health Sciences totaled \$45.9 million, followed by the Department of Internal Medicine, \$36.3 million, the Department of Physiology and Pharmacology \$20.4 million, and the Department of Pathology, \$10.1 million.

INDUSTRY RELATIONS NAMES NEW DIRECTOR

Ms. Janice Grace will join Wake Forest University Health Sciences as Director, Industry Relations, effective November 1, 2004. Janice comes to Wake Forest University Health Sciences from the Mayo Clinic in Rochester, Minnesota, where she, as Technology and Licensing Manager, was responsible for a significant portfolio. She previously served as Research Contract Manager at the Mayo Clinic working specifically with industry sponsored research contracts. Janice has extensive experience in legal administration as well. Ms. Grace will be responsible for promoting Wake Forest University Health Sciences' expertise and facilities to industrial sponsors to foster both basic and clinical research collaborations and partnerships. She will hold primary responsibility assuring that research performed at Wake Forest for industrial sponsors meets all university, local, and federal guidelines, rules, policies, and laws. Ms. Grace will oversee the day-to-day operations of the Section on Industry Relations.



CONCERN LINES

ANIMAL CARE & USE -
716-5899
RESEARCH CONDUCT -
716-0338
COMPLIANCE -
1-877-880-7888

REGULATORY COMMITTEE DEADLINES

ANIMAL CARE AND USE
COMMITTEE -
NOVEMBER 7 AND DECEMBER 5,
2004

INSTITUTIONAL REVIEW BOARD -
NOON - FRIDAYS

INTRAMURAL RESEARCH SUPPORT COMMITTEE DEADLINES

*REGULAR AND INTERIM -
NOVEMBER 12, 2004

* Clinical studies or other
research involving humans
are encouraged

UPDATE ON SIGNATURE PROCESS FOR GRANT AND CONTRACT DOCUMENTS

Please continue to leave the face page blank (institutional name and title) on all applications, and the Office of Research will complete this section. In most circumstances, either Paula Means, Assistant Dean for Research or Kim Vargas, Director, Grants Administration will act as signatory on behalf of the institution. In the event that these individuals are not available, other official signatories will be utilized. If possible, do not enter either name onto the form as it may require the face page to be revised and brought back down for signature.

In the months to come, we will continue to evaluate our processes and provide updates as we implement changes and improvements to better meet the needs of the faculty.

Thank you for your cooperation during this transition.

NEW PROCEDURE

To ensure that the Office of Research has a complete copy of all grant applications in the files, the original and 1 copy of all applications will be required when submitted for Institutional approval.

GRANTS MANAGEMENT OFFICER FROM NIH TO SPEAK AT WFUHS

Dorothy Duke, Chief Grants Management Officer, Grants Management Branch, National Institute on Environmental Health and Safety will present the latest administrative, funding, and policy changes affecting the National Institutes of Health and its grantees in the current and future years. The session will be held **Thursday, November 11 at 10:00 am in Commons Conference Rooms 2 and 3.**

OFFICE OF RESEARCH OPEN HOUSE

The Office of Research is having an open house on **Wednesday, December 1, 2004, from 10:00am to 2:00pm**. All medical center employees are invited to visit the Office of Research on E Floor of the Gray building and the Industry Relations office on E Floor of the Hanes building.

Please take this opportunity to come visit familiar faces and help welcome our new staff additions! There will be refreshments and door prizes. We hope to see you there!!

REMINDER

NIH Loan Repayment Programs - December 15, 2004

NIH started accepting applications for its Loan Repayment Programs in September 2004. These NIH Loan Repayment Programs (LRPs) are a vital component of our nation's efforts to attract health professionals to research careers in the areas of national need. The programs are the Clinical Research LRP, Pediatric Research LRP, Contraception and Infertility Research LRP, Clinical Research for Individuals from Disadvantaged Backgrounds LRP, and Health Disparities Research LRP. The LRPs can repay up to \$35,000 a year for qualified educational debt for health professionals pursuing research in one of the specified areas. The programs also provide coverage for Federal and State tax liabilities. Applicants must have a doctoral-level degree, devote 50% or more of their time to non-profit- or government-funded research, and have educational debt equaling at least 20% of their institutional base salary. Complete information about the LRPs and the online application process can be found at <http://www.lrp.nih.gov>.

LICENSING REVENUE SURGE 77 PERCENT AT WAKE FOREST

Licensing revenues at Wake Forest University increased by 77 percent in the fiscal year ending June 30, 2004, reaching \$34,296,000. In fiscal year 2003, licensing revenues were \$19,318,000. "These increases in revenue have been a great benefit to Wake Forest" said Michael Batalia, Ph.D., acting director of the Office of Technology Asset Management "This income has allowed us to develop more resources." The Office serves all of Wake Forest, but nearly all the revenues were generated by patents from Wake Forest University Health Sciences. The annual report also showed that 30 inventions were disclosed, nine patents were issued, seven new applications were filed for patents, and use of seven patents were either licensed or optioned.

RESEARCH ADMINISTRATORS MEETINGS

NOVEMBER 11 -

NIH UPDATE, DOROTHY DUKE,
NIEHS

DECEMBER 9 -

THANK YOU BRUNCH (ARDMORE
CAFETERIA, DETAILS WILL BE
PROVIDED AT A LATER DATE)

MEETINGS ARE HELD AT 10:00 AM IN
THE NUTRITION RESEARCH CENTER
CONFERENCE ROOM #3. PLEASE
EMAIL AMY COMER IF YOU WOULD
LIKE TO BE ADDED TO THIS EMAIL
GROUP.

(ACOMER@WFUBMC.EDU)

PHASE 1 SBIR'S IN NC SURGE 75% IN 2003

UNOFFICIAL CALCULATIONS FROM THE US
SMALL BUSINESS ADMINISTRATION
(SBA) SHOW A 75 PERCENT INCREASE
IN SBIR (SMALL BUSINESS INNOVATION)
PHASE 1 AWARDS IN NORTH CAROLINA
FOR 2003. NORTH CAROLINA'S RAPID
RISE TO THE TOP RUNG OF SBIR RE-
CIPIENTS NATIONWIDE IS ATTRIBUTABLE TO
THE EFFORTS MADE BY THE SMALL BUSI-
NESS AND TECHNOLOGY DEVELOPMENT
CENTER'S SBIR PREPARATION ASSIS-
TANCE AND EFFORTS TO EDUCATE SMALL
BUSINESS RESEARCH BUSINESSES ABOUT
THIS FUNDING MECHANISM. MORE INFOR-
MATION ABOUT THIS SERVICE CAN BE
FOUND AT [HTTP://WWW.NCSBIR.ORG](http://www.ncsbir.org).
EVERY PROJECT FUNDED VIA THE SBIR
AND STTR (SMALL BUSINESS TECHNOL-
OGY TRANSFER) PROGRAMS MUST COM-
MENCE WITH A PHASE 1 AWARD. WHILE
PHASE 1 AWARDS RANGE FROM
\$60,000 TO \$100,000, THEY OPEN THE
DOOR TO THE OPPORTUNITY TO RECEIVE
A MUCH MORE SUBSTANTIAL AWARD IN
PHASE 2, OFTEN \$750,000 AND, IN
SOME CASES, MORE.

DEAR DR. OR



Dear Dr. OR:

I would like to charge the fee for reprints on a publication to my NIH grant which funded the research, is this an allowable charge?

Signed,
Wanting to Charge

Dear Wanting to Charge:

This is an allowable charge. Note also that all publications resulting from research supported by NIH must include a statement at the end of the article acknowledging NIH grant support, and a disclaimer as follows:

“This publication was made possible by Grant Number _____ from _____ (the institute involved)” or “The project described was supported by Grant Number _____ from _____ (the institute involved)” . “Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the [name of awarding office or NIH].”

Dear Dr. OR:

During the process of routing my NIH grant application through the Office of Research for review and approval, I was informed that the Institutional Official would not review or sign because I had not signed the face page. I feel I had to make an unnecessary trip back to the Office of Research to sign my application face page so that the Institutional Official could complete the review and sign. Was this really necessary?

Signed,
Frustrated PI

Dear Frustrated:

We are sorry you had to make an additional trip to the Office of Research to sign your face page. It is imperative that the PI has signed and dated the face page of a grant application before routing the application to the Office of Research. In the past, an application was returned without review from NIH because the PI signed and dated the face page after the Institutional Official. NIH guidelines state that the PI's signature can not be dated after the Institutional Official's signature.



Women's Health Educational and Research Opportunities for Clinicians and Scientists

*For upcoming conferences and lectures, visit
our calendar website at
www.wfubmc.edu/women*

NOVEMBER IS AMERICAN DIABETES MONTH

Today, diabetes is one of the most serious health challenges facing women in the United States, especially women of color. Complications from diabetes rank among the top 10 causes of death for all women. Diabetes-related health risks are twofold: health risks that can lead to diabetes and health risks that result from having diabetes. Cardiovascular disease is one of many diabetes-associated risks. Unfortunately, women are not well informed and do not make the connection between diabetes and heart disease. Patient's lack of awareness suggests that doctors are not communicating. The best defense for female baby boomers is prevention, followed by early detection, treatment, and more prevention through self-management. To learn more about diabetes, visit <http://www.4woman.gov/pub/steps/Diabetes.htm>.

ACOG CLARIFIES RECOMMENDATIONS ON CERVICAL CANCER SCREENING IN ADOLESCENTS

The American College of Obstetricians and Gynecologists (ACOG) issued a committee opinion to help clear up confusion over when adolescent girls should receive their first Pap test vs. when they should have their first gynecologic visit. New guidelines recommend that a baseline Pap be performed approximately three years after intercourse or by age 21, whichever occurs first. ACOG strongly recommends that an adolescent girl's first visit to an ob-gyn for health guidance, screening, and preventive health occur between ages 13 and 15, ideally before sexual activity has occurred. http://www.acog.org/from_home/publications/press_releases/nr09-30-04-1.cfm.

RESEARCH SEMINAR SERIES

WHCoE Research Seminar Series debuts November 15th with a presentation by Adolfo Fernandez, MD "Dr. Fuzz," (Dept. of General Surgery) entitled "**Bariatric Surgery.**" In the Commons Conference Room 1, Nutrition Bldg., Ground Floor, Noon - 1:00 pm. Lunch will be provided.

CONGRATULATIONS!

The Women's Health Center of Excellence presented Alex Rogers (Class of 2007) with a \$100 gift certificate to the bookstore for her poster on women's health at the Medical Student's Research Awards Day on October 6th. The poster is entitled "*Barriers to Voluntary Counseling and HIV Testing Among Antenatal Women in India.*" and is on display in the Coy C. Carpenter Library Learning Resources Center.

CONTROLLER'S CORNER - GRANTS MANAGEMENT

WELCOME AARON!

The Controller's Office is pleased to announce the addition of Aaron Prevet, Grant Accountant 1; Aaron joined our office in late September.

FYI

Your grant accountant may contact you to ask for a new chartfield on a charge citing that we are closing out the month. It is imperative that we receive this information promptly as we cannot close the books until we have reconciled all of the charges and have active and appropriate chartfields assigned to them. Most journals are not received until the end of the month which leaves us with a small turnaround time. If you know you will not be available during this period of the month, please let your grant accountant know who they should contact. Below is a list of these dates:

Thursday November 4th
Monday December 6th
December 20th - December 23rd
Friday February 4th
Friday March 4th
Wednesday April 6th
Thursday May 5th
Monday June 6th

Making sure that your PIs and departmental staff use current grant numbers and update the grant numbers with service departments is a great way ensure your accounts are properly processed in a timely manner.

UPGRADE TO 8.8 PEOPLESOFT FINANCIALS:

Please be advised that the Institution will be upgrading to PeopleSoft Financials 8.8 effective January 3rd. There are several critical dates that you need to be aware of that affect your access to the system. You will be receiving more information on this in the coming months.

- December 1st will be the last day to enter any JCR or retros into the system until January 3rd
- All Request for payments (RFPs) must be stamped in at the Controller's office by 5 pm December 17th in order to make the last check run of the year on December 22nd
- December 20th will be the last day to enter requisitions until Jan 3rd

There will be training classes on the new system announced in the upcoming months. If you access the system for anything we strongly encourage you to attend these sessions as the new system is web based and different than what you are accustomed to now. Please feel free to contact us with any questions.

COMING SOON:

We are working on an automated effort reporting system for all monthly employees. We plan to have it in place by the next reporting period which will be in January 2005.

Please remember effort certification is a requirement of receiving federal funds and needs to be attended to in a timely manner and with utmost attention. When you certify your effort you are stating: *this is how I spent my time*. There should not be a reason for this certification to change as the question will be asked "what do you know now that you did not know then about how you spent your time?" Since we certify after the fact there should never be a need to change certifications. Funded projects that do not have chartfields yet should always be included on the effort report (use the GTS# or funding agency & title of project).

NEWS FROM NIH

NIH ANNOUNCES UPDATED CRITERIA FOR EVALUATING RESEARCH GRANT APPLICATIONS

The goal of the NIH Roadmap is to accelerate and strengthen biomedical research enterprise. During consultation with the extramural scientific community that led to the development of the NIH Roadmap process, it was frequently mentioned that the criteria used to evaluate research grant applications were not placing appropriate emphasis on some important types of biomedical research (see <http://nihroadmap.nih.gov>). The Roadmap Trans-NIH Clinical Research Workforce Committee proposed a modification of the NIH Peer Review Criteria for investigator-initiated research grant applications that would better accommodate interdisciplinary, translational, and clinical projects. The updated review criteria were adopted at the August 5, 2005 meeting of the Directors of the NIH Institutes and Centers. These updated review criteria will be effective for research grant applications received on or after January 10, 2005 that fall into the following categories:

- Investigator initiated research grant applications;
- Investigator initiated research grant applications submitted in response to Program Announcements (PAs) whether published before or after this announcement
- Solicited research grant applications submitted in response to Request for Applications (RFAs) will continue to use the criteria described in the RFA

Beginning with reviews in the summer of 2005, reviewers will be instructed to use the updated criteria as the basis for evaluating research grant applications and for assigning a single, global score for each scored application. In their written critiques, reviewers will be asked to comment on each of the criteria in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in assigning the overall score, weighting them as appropriate for each application. Note that an application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score. The criteria is as follows: Significance; Approach; Innovation; Investigators; Environment; Protection of Human Subjects from Research Risk; Inclusion on Women, Minorities, and Children in Research; Care and Use of Vertebrate Animals in Research; and Budget. This complete notice, including more details on the criteria can be found at <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-05-002.html>. A side-by-side document comparing the changes with the criteria in use since 1997 is available at http://grants.nih.gov/grants/peer/comparison_evaluation.doc. Feedback and comments regarding the criteria may be sent to grantsinfo@nih.gov.

NIH, OFFICE OF BIOTECHNOLOGY ACTIVITIES(OBA)

Compliance with the NIH Guidelines for Research Involving Recombinant DNA Molecules – NOT-OD-04-067

The NIH Guidelines for Research Involving Recombinant DNA Molecules stipulate biosafety and containment measures for recombinant DNA research. Furthermore, they outline essential ethical principles and key safety reporting requirements for human gene transfer research. Investigators are reminded that they must adhere to the NIH Guidelines when they perform research involving recombinant DNA molecules that is conducted at, or sponsored by, an entity receiving any NIH support for recombinant DNA research. Therefore, even privately funded projects employing recombinant DNA must adhere to the NIH Guidelines if they are being carried out at, or funded by, an organization that has any NIH contracts, grants, or other support for this kind of research. A fully indexed and easily navigated version of the NIH Guidelines can be accessed at <http://www4.od.nih.gov/oba/rac/guidelines.html>. This complete notice can be found at <http://grants2.nih.gov/grants/guide/notice-files/NOT-OD-04-067.html>.

Research Funding Opportunities

For all funding information contact Angela Horton, Office of Research, 62382, unless noted otherwise in the funding announcement

THE MCKNIGHT ENDOWMENT FUND FOR NEUROSCIENCE

POSITION: Technological Innovations in Neuroscience Awards

DESCRIPTION: The Fund supports innovative research designed to bring science closer to the day when diseases of the brain can be accurately diagnosed, prevented, and treated. To this end, the Fund invites letter of intent for the 2005 McKnight Technological Innovations in Neuroscience Awards. Awards are for up to two years for up to \$100,000. Applicants must be tenured or tenure-track positions. Complete information on how to submit the letter of support can be found at <http://www.mcknight.org/neuroscience/>.

DEADLINE: December 1, 2004

INTERNATIONAL UNION AGAINST CANCER (UICC)

POSITION: UICC International Cancer Technology Transfer Fellowships

DESCRIPTION: These fellowships are funded by a group of cancer institutes, leagues, societies, associations, foundations, and government agencies in North America, Europe, and Australia. The aims of the awards are threefold:

- To facilitate rapid international transfer of cancer research and clinical technology
- To exchange knowledge and enhance skills in basic, clinical, behavioral, and epidemiological areas of cancer research, and in cancer control and prevention
- To acquire up-to-date clinical management, diagnostic and therapeutic expertise

Applications are particularly encouraged for projects in the fields of cancer control and prevention; epidemiology and cancer registration, public education, and behavioral sciences. The short-term fellowships permit successful candidates to spend up to 3 months at a suitable host institute abroad. They are particularly aimed at investigators and clinicians working in places where such teaching is not yet available and where the necessary facilities exist to apply and disseminate the new skill upon return. Qualified cancer investigators should be in the early stages in their careers whilst clinicians should be well established in their oncology practice. The average award value for one month stipend and travel is \$3,000, the maximum length is 3 months. Additional information can be found at <http://fellows.uicc.org>.

DEADLINE: Open

GRASS FOUNDATION

POSITION: Grass Fellowships in Neuroscience

DESCRIPTION: These fellowships are for individuals in the late predoctoral or early postdoctoral category who are academically prepared for independent research in neurophysiological investigation. Neurobiological approaches used to elucidate nervous system function may include electrophysiology, experimental neuroanatomy, neurochemistry, cellular neurobiology, developmental neurobiology, tissue culture and behavioral analysis. The fellowship provides funds to support for one summer an investigator and family at the Marine Biological Laboratory in Woods Hole, MA. Laboratory research space rental, housing and board are provided. The normal tenure is fourteen weeks and preference is given to those applicants that commit to the full 14-weeks. Additional information can be found at <http://www.grassfoundation.org>.

DEADLINE: December 15, 2004

NATIONAL SLEEP FOUNDATION

POSITION: Pickwick Postdoctoral Fellowship

DESCRIPTION: The Foundation supports and encourages sleep research by offering this fellowship to persons interested in pursuing basic, clinical and applied sleep research. Pickwick Postdoctoral Fellows receive funding based on NIH guidelines plus a benefits allowance for two years. Additional information can be found at <http://www.sleepfoundation.org>.

DEADLINE: December 1, 2004

PFIZER

POSITION: Scholar Grants

DESCRIPTION: These awards are meant to support the career development of junior faculty in pain medicine; clinical psychiatry or clinical rheumatology. Awards of up to \$130,000 for two years will be awarded to individuals who are pursuing research relevant to human health in one of the three areas. The applicant must demonstrate that at least 75% of his or her professional time will be devoted to research. Interdisciplinary and translational research proposals are encouraged. The applicant should hold a junior faculty position (within two years of appointment as an instructor, an assistant professor, or an equivalent rank). Additional information can be found at <http://www.pfizerpublichealth.com>.

NOTE: Only one application per department/section can be submitted by the Institution, please contact the Office of Research (ahorton@wfubmc.edu) by December 1, 2004 if you plan to submit.

DEADLINE: January 5, 2004

Research Funding Opportunities

For all funding information contact Angela Horton, Office of Research, 623382, unless noted otherwise in the funding announcement

Research Funding Opportunities

For all funding information contact Angela Horton, Office of Research, 62382, unless noted otherwise in the funding announcement

NCI

POSITION: Quick-Trials for Novel Cancer Therapies: Exploratory Grants – PAR-04-155

DESCRIPTION: Continuing progress in basic cancer research and drug development has led to discoveries of new agents or approaches for molecular targeting in novel cancer therapies. These new agents or approaches suppress tumor growth through multiple mechanisms such as cell cycle control, activation of tumor suppressor genes, essential signal pathway blockage, tumor vaccines, tumor microenvironment modification, etc. Rapid translation of these exciting discoveries into clinical practice requires timely support to accommodate the special needs of novel cancer therapy development. The PA is intended to provide investigators with rapid access to support for pilot, Phase I and Phase II cancer clinical trials as well as support for patient monitoring and laboratory studies linked to a cancer clinical trial. Phase III are not excluded but such trials generally require greater resources and duration than available from an R21 award. This PA is aimed at providing a new approach in the grant application process by offering a rapid turnaround from application submission to funding. Investigators may apply for a maximum of two years of funding for up to \$250,000 per year. The complete PA can be found at <http://grants2.nih.gov/grants/guide/pa-files/PAR-04-155.html>.

DEADLINES: December 9, 2004; April 9, August 9 and December 9, 2005

NINDS

POSITION: Axonal Damage in Multiple Sclerosis: Strategies for Protection and Repair – PAS-05-002

DESCRIPTION: This Program Announcement invites applications proposing clinical and translational research in multiple sclerosis (MS) that target the neurodegenerative aspect of the disease. Applications in basic neuroscience or glial biology are not covered under this PA. Applications in response to this PA will apply ideas, insights, and discoveries generated through basic scientific inquiry to the treatment of MS and will have an emphasis on activities directly focused on the development of neuroprotective and regenerative therapies for MS. Applications testing novel therapeutic interventions in animal models or in vitro systems are encouraged as are applications for the development of technologies that would facilitate the monitoring of their efficacy. This funding mechanisms for this PA will be the Exploratory/Developmental Grant Program (R21) and the Research Project Grant (R01). The complete PA can be found at <http://grants2.nih.gov/grants/guide/pa-files/PAS-05-002.html>.

DEADLINES: February 1, June 1 and October 1, 2005

NIGMS, NIEHS, OFFICE OF DIETARY SUPPLEMENTS (ODS)

POSITION: Metals in Medicine – PA-05-001

DESCRIPTION: The objective of the PA is to encourage research that bridges the areas of inorganic chemistry and medicine. The mechanisms by which organisms control transition metal ions and the roles of these metals in cellular regulation and signaling in health and disease are of principal interest. These areas are linked by the need to involve researchers having a deep understanding of inorganic chemistry in medically relevant research. Much of the work is expected to involve collaborations including chemists, biologists, and medical researchers. The results will be relevant to understanding the mechanisms of metal handling by biological systems and the basic cellular roles underlying the nutritional requirement for essential metals. It is expected that this research will also contribute to the identification of new targets for drug discovery, diagnostics, and future therapeutic approaches involving metal complexes, although drug development, per se, is not a focus of the program. This PA will use the Research Grant (R01); Exploratory/Developmental (R21) and Program Project (P01) award mechanisms. The full Program Announcement can be found at <http://grants2.nih.gov/grants/guide/pa-files/PA-05-001.html>.

DEADLINES: February 1, June 1 and October 1, 2005

Research Funding Opportunities

For all funding information contact Angela Horton, Office of Research, 62382, unless noted otherwise in the funding announcement

GRANT AND CONTRACT PROPOSAL WATCH

	Fiscal Year 05 July - Aug	Fiscal Year 04 July - Aug	% Change
Proposals Submitted	134	108	24.1
Dollars Requested	\$50,788,788	\$53,523,531	[5.1]

Research Funding Opportunities

For all funding information contact Angela Horton, Office of Research, 62382, unless noted otherwise in the funding announcement

REMINDER

"THREE DAY RULE" FOR APPLICATIONS

Applications must be submitted for review and institutional signature not less than **three days prior** to the agency deadline.

KEY FOR DEPARTMENT OF HEALTH AND HUMAN SERVICES

(DHHS) INSTITUTES - (<http://www.nih.gov/icd/>)

AHRQ - Agency for Healthcare Research and Quality

NCCAM - National Center for Complementary and Alternative Medicine

NCI - National Cancer Institute

NCNR - National Center of Nursing Research

NCRR - National Center for Research Resources

NEI - National Eye Institute

NHLBI - National Heart, Lung and Blood Institute

NHGRI - National Human Genome Research Institute

NIAAA - National Institute on Alcohol Abuse and Alcoholism

NIA - National Institute on Aging

NIAID - National Institute of Allergy and Infectious Diseases

NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases

NIBIB - National Institute of Biomedical Imaging and Bioengineering

NICHD - National Institute of Child Health and Human Development

NIDA - National Institute on Drug Abuse

NIDCD - National Institute on Deafness and Other Communication Disorders

NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases

NIDCR - National Institute of Dental and Craniofacial Research

NIHES - National Institute of Environmental Health Sciences

NIGMS - National Institute of General Medical Sciences

NIMH - National Institute of Mental Health

NINDS - National Institute of Neurological Disorders and Stroke

NLM - National Library of Medicine

ORWH - Office of Research on Women's Health

PURSUIT STAFF

AMY COMER

KIM VARGAS

LAWRENCE D. SMITH

